Gyrus Capital, a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors, has held a final close on a €700m single-asset continuation vehicle for Essential Pharma. With over €100m raised in incremental commitments in Q1 25, the continuation vehicle closed slightly above the hard cap.
Essential Pharma focuses on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas.
The continuation vehicle was originally led by AlpInvest and supported by a significant participation from StepStone Group and other high-quality new and existing investors, as well as a meaningful reinvestment from both Gyrus and management. The second close was comprised of returning investors and a select group of new investors
Initially formed in December 2024 to support the recapitalisation of Essential Pharma, alongside a €300m strategic financing facility with Sixth Street, the continuation vehicle will also enable Essential to deploy additional capital to build on its diversified portfolio across established and rare disease medicines through its successful acquisition and development strategy, supporting Essential’s mission to ensure access to essential medicines for patients across new and existing markets.
Since CEO Emma Johnson was appointed in 2023, the company has expanded into rare diseases, with the addition of marketed product Colobreathe® and Hu14.18, an immunotherapy in late-stage clinical development for the treatment of high-risk neuroblastoma.
